Sankyo Benicar HCT approved
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Sankyo's Benicar HCT (olmesartan/hydrochlorothiazide) will be available in second half 2003. FDA cleared the combination of Sankyo's angiotensin II receptor blocker Benicar and HCTZ June 5 for second-line treatment of hypertension. FDA's Benicar review suggested that the ARB is similar to other agents in the class (1Pharmaceutical Approvals Monthly Sept. 1, 2002, p. 35). Benicar HCT will be available in three fixed-dose combinations: 20 mg olmesartan/12.5 mg HCTZ, 40 mg/12.5 mg and 40 mg/25 m
You may also be interested in...
Sankyo Benicar Offers No Significant Advantage Over Other ARBs, FDA Says
Sankyo’s antihypertensive Benicar (olmesartan medoxomil) may not offer significant benefits over the other six approved angiotensin II receptor blockers, FDA said in review documents for the NDA.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.